Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy

Abstract

Objective. To evaluate the efficacy and safety of the telmisartan plus amlodipine (T/A) single-pill combination (SPC) in Asian patients with hypertension whose blood pressure (BP) was not adequately controlled on either monotherapy or on low-dose combination therapy. Patients and Methods. Data are presented from five Boehringer Ingelheim-sponsored phase 3, double-blind, 8-week, studies: two studies in nonresponders to amlodipine (data pooled for amlodipine), two studies on nonresponders to telmisartan (pooled data), and one on nonresponders to low-dose T/A SPC. Results. After 8 weeks' treatment, mean reductions from the reference baseline in diastolic BP (DBP; primary endpoint), systolic BP (SBP), and SBP, DBP goal, and response rates were higher with the T/A SPC than respective monotherapies. The T80/A5 SPC resulted in greater reductions in DBP and SBP, and higher DBP goal and response rate than the low-dose T40/A5 SPC. Peripheral edema incidence was low (amlodipine 0.5%, telmisartan 0.0%, and T/A SPC 0.7%). Discussion and Conclusion. In Asian patients whose BP is not adequately controlled with telmisartan or amlodipine monotherapy, T/A SPC treatment results in greater BP reduction, and higher DBP and SBP goal and response rates. The safety and tolerability of the T/A SPC are comparable to those of the respective monotherapies and consistent with those reported in previous studies.

Formulations of Amlodipine: A Review

“…Not much information regarding the formulations is available as the studies are more clinically oriented and the combinations have been discussed with respect to their clinical outcomes only in majority of the cases. The drugs most commonly employed in combination with AD (i.e., single drug + AD combination) include aliskiren [39–41], atorvastatin [42–52], azilsartan [53], benazepril [54, 55], fimasartan [56], indapamide [57, 58], irbesartan [59], olmesartan (olmesartan medoxomil) [39, 60–67], perindopril [68–72], telmisartan [73–77], and valsartan [70, 71, 78–97]. …”

Swelling Mechanism of Core–Shell Polymeric Nanoparticles and Their Application in Enhanced Oil Recovery for Low-Permeability Reservoirs

“…Hu et al prepared a novel aqueous hydrolyzed polyacrylamide-based SiO 2 nanosuspension for EOR, and its rheological properties were investigated under different salinities and temperatures . Zhu et al formulated a polymer-grafted nanoparticle suspension by grafting a novel vinyltriethoxysilane-functionalized SiO 2 onto acrylamide (AM)/acrylic acid copolymer with the aim of obtaining a polymeric nanofluid with temperature and salt tolerance . Alaskar et al investigated the flow of polymeric nanoparticles through porous and fractured media and found that particle size, particle size distribution, shape, and surface charge were the main parameters affecting the transportation of polymeric nanoparticles through the porous media .…”

“…30 Zhu et al formulated a polymer-grafted nanoparticle suspension by grafting a novel vinyltriethoxysilane-functionalized SiO 2 onto acrylamide (AM)/acrylic acid copolymer with the aim of obtaining a polymeric nanofluid with temperature and salt tolerance. 31 Alaskar et al investigated the flow of polymeric nanoparticles through porous and fractured media and found that particle size, particle size distribution, shape, and surface charge were the main parameters affecting the transportation of polymeric nanoparticles through the porous media. 32 Liu et al performed rheological studies on a novel core−shell polymer-grafted nanoparticle synthesized from in situ free-radical polymerization-functionalized SiO 2 nanoparticle and acrylamide-based polymer molecules.…”